DISEASE COURSE AND OUTCOMES OF PREGNANCY IN JUVENILE IDIOPATHIC ARTHRITIS: ANY DIFFERENCE AMONG DISEASE SUBSETS?

Antía García Fernández1, Laura Andreoli2,3, Maria Chiara Gerardi2,3, Sonia Zamb4, Franco Franceschini2,3, Angela Tincani2,3, Ramón y Cajal University Hospital, Rheumatology, Madrid, Spain; "Spedali Civili di Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 5University of Brescia, Brescia, Italy; "Spedali Civili di Brescia, Obstetrics and Gynecology, Brescia, Italy.

Background: Data on the disease activity and pregnancy outcomes taking into account the different types of Juvenile idiopathic arthritis (JIA) patients are limited.

Efficacy measure: JIAACR-Score:

<table>
<thead>
<tr>
<th>Disease activity</th>
<th>JIA ACR 20</th>
<th>JIA ACR 90</th>
<th>JIA ACR 20</th>
<th>JIA ACR 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment duration (months)</td>
<td>0%</td>
<td>20%</td>
<td>50%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Adverse events of special interest were uveitis (n=109), H. zoster (n=24), chronic inflammatory bowel disease (n=19), pregnancies (n=4), depression (n=11), malignancies (n=8), demyelination (n=2). Adverse Events of Special Interest (AESI) were in the MTX-cohort uveitis (n=52), H. zoster (n=4), chronic inflammatory bowel disease (n=1), depression (n=2), malignancies (n=4).

A total of 1606 patients (60.7%) discontinued treatment. Of these 638 (39.3%) continued due to remission, 565 (35.2%) due to lack of efficacy and 188 (11.7%) because of intolerance.

Conclusion: The current analysis adds to the established safety profile of Etanercept and demonstrates that the rate of SAEs is comparable and consistent with the overall AE profile in paediatric patients. As expected, infections are the most frequent SAE. Uveitis is likely associated with JIA. Of notice, few patients developed a chronic inflammatory bowel disease and some a malignancy. No new safety signals specific to the paediatric population were identified in this large cohort of JIA patients.

REFERENCES:

Acknowledgement: The authors acknowledge the support of the patients, parents and all contributors.


At conception 19 (95%) pregnancies were on remission, 1 (5%) OLA patient in low disease activity. Among the 20 pregnancies ended with a live birth, 1 OLA, 4 SYS and 1 ERA patients maintained sustained remission, without cDMARDs or bDMARDs, throughout pregnancy. There were 7 flares in 6 (31.8%) pregnancies, 5 (71.4%) of them among PL A patients and 2 (28.6%) among OLA-E patients. No extrarticular flare was recorded. There was no flare among SYS, OLA and ERA patients. One pregnancy in a patient with PLA JIA (4.5%) was characterized by a flare, but none had more than two flares. Most of flares (2/29% 1 trimester, 4/57% 2 trimester, 1/14% 3 trimester) occurred during the 2 trimester. Eight flares occurred in postpartum, also in 2 pregnancies more than one flare, but none had more than two flares. Most of flares (2/29% 1 trimester, 4/57% 2 trimester, 1/14% 3 trimester) occurred during the 2 trimester. Eight flares occurred in postpartum, also in 2 pregnancies more than one flare, but none had more than two flares.
Regarding pregnancy complications and outcomes, no cases of Preeclampsia, eclampsia, small for gestational age babies, intratuerine death, were observed. One pregnancy was complicated with pre-term premature rupture of membranes at 35 gestational week, in a patient not taking prednisone. There were 5 (25%) pre-term deliveries.

**Conclusion:** Nearly one third of pregnant patients with JIA had a disease flare during pregnancy. Flares were observed only in 2 disease subsets (PLA; CLA-E) and associated with discontinuation of bDMARDs at positive pregnancy index. The preconception counseling of patients with JIA should include the disease subset in the risk stratification and consequently the continuation of bDMARDs during pregnancy. Maternal disease control is necessary to minimize the risk of adverse pregnancy outcomes (especially pre-term birth).

**Disclosure of Interests:** Antia Garcia Fernández: None declared, Laura Arroyo: None declared, Nuno Cabral: None declared, Franci Crasulli: None declared, Cecilia Nalli: None declared, Matteo Filippini: None declared, Roberto Goria: None declared, Marco Taglietti: None declared, Micaela Fredi: None declared, Maria Grazia Lazzaroni: None declared, Andrea Lojacono: None declared, Sonia Zatti: None declared, Franco Franceschini: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, Oks, Alpha Sigma, Lilly, Jannsen, Cellgene, Novartis.

**DOI:** 10.1136/annrheumdis-2019-eular.6891

---

**THU0521**

**EARLY IDENTIFICATION OF VENTRICULAR DYSFUNCTION IN JUVENILE SYSTEMIC SCLEROSIS BY SPECKLE TRACKING ECHOCARDIOGRAPHY**

**Giovanni Civieri**, 1 Biagio Castaldi 2, Giorgia Martin 1, Omella Milanesi 1, Giovanni Cioccaru 3, None declared.

**Background:** Juvenile Systemic Sclerosis (JSSc) is a rare multisystemic connective tissue disease, with onset before the age of 16. Cardiac involvement is recognized in 8-24% of the patients [1], begins in early stages of JSSc and has a poor prognosis. The traditional cardiac US imaging, including the left ventricular ejection fraction (EF), evaluates the global function of the heart, thus being inappropriate to assess the subclinical course of the disease. A new echocardiographic technique, the speckle tracking echocardiography (STE), has been shown to be able to identify regional ventricular dysfunctions also in early stages of adult-onset SSc [2,3].

**Objectives:** Aim of our study was to assess the longitudinal strain of right and left ventricle in JSSC patients, in order to identify ventricular dysfunctions earlier and more effectively than with traditional echocardiography. Furthermore, we investigated the evolution of cardiac involvement of patients with JSSC, assessing the presence of regional abnormalities in the subendocardial layer, as assessed by STE.

**Methods:** Consecutive patients with JSSC underwent clinical and cardiology evaluation. This included traditional echocardiography (such as M-Mode, EF, Pulsed- and Tissue-Doppler), 3D-Echocardiography and STE, measuring the global longitudinal strain of left ventricle (GLS) and the longitudinal strain of right ventricle free-wall (RVLS). Each patient was assessed several times by pediatric rheumatologists for J4S and by cardiologists with STE and standard echo.

**Results:** 18 JSSC patients (12 F, 6 M), mean age 12.3 years, disease duration 4.5 years, entered the study. At baseline evaluation, EF was abnormal in 1 patient, whereas GLS and RVLS were abnormal in 5. The diagnostic sensitivity of cardiac involvement of STE increased, with a prevalence rising from 22.2% to 38.8%. During the follow-up, lasted duration 4.5 years, entered the study. At baseline evaluation, EF was not identified by EF. It is possible that the coronary microvascular damage compromises the subendocardial fibers function which are more sensitive to ischemia and whose contractility is well assessed by GLS [5]. Finally, the initial correlation between strain and J4S disappeared during the follow-up, maybe because of the pharmacological therapy, which was effective on several aspects of the disease but had low impact on the ventricular function.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2019-eular.6678

---

**THU0520**

**PREDICTIVE VALUE OF SPECIFIC ANTIBODIES AND ASSOCIATED CLINICAL PHENOTYPES FOR DETERMINATION OF A PHENOTYPIC DATABASE WITH SPECIAL REGARD TO MYOSITIS-SPECIFIC ANTIBODIES AND ASSOCIATED CLINICAL PHENOTYPES**

Claudia Sengler 1, Svea Horn 1, Nadine Grösch1, Jens Klotzsche 1, Martina Niewerth 1, Fabian Speth 1, Peter Haas 2, Clais Hinze 2, Gerd Hornett 2, Tilmann Kallinich 3, Frank Weller-Heinemann 4, Nadine Unterwalder 4, Kirsten Minden 4, 1German Rheumatism Research Center, Berlin, Germany; 2University of Rostock, Rostock, Germany; 3German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany; 4University of Münster, Department of Pediatric Rheumatology and Immunology, Münster, Germany; 5Center for General Pediatrics and Neonatology, Asklepios Klinik, Sankt Augustin, Germany; 6Charité – Universitätsmedizin Berlin, Department of Pediatric, Division of Pneumology and Immunology, Berlin, Germany; 7Prof.-Hess-Kinderklinik, Berlin, Germany; 8Labor Berlin, Berlin, Germany

**Background:** Next to weakness of the proximal muscles and typical skin lesions as leading symptoms in juvenile dermatomyositis (JDM) there can be involvement of other organ systems and tissues. Myositis-specific antibodies (MSA) may help to distinguish clinically distinct phenotypes.

**Objectives:** 1) to analyse the clinical presentation of JDM and how diagnosis was verified and 2) to determine the spectrum of MSA and the associated clinical phenotypes in a German cohort of JDM patients.

**Methods:** We analyzed data of the national pediatric rheumatology database (NPRD), where children and adolescents with chronic rheumatic diseases are documented yearly by means of disease-specific questionnaires. Cross-sectional data of patients with JDM documented between 2014 and 2016 were analyzed. MSA were determined by a commercial multiplex array. To further specify the phenotype and patient’s outcome, an additional retrospective chart review was conducted.

**Results:** We identified 186 patients with a diagnosis of JDM (69% female). Mean age at disease onset was 6.8 ± 3.5 years, mean time between first symptoms and first contact to a pediatric rheumatologist was 6.1 ± 8.9 months, mean age at documentation was 11.5 ± 4.4 years. The following diagnostic procedures were pathologic/positive for JDM: Histology 44/147 (30%), electromyography 28/144 (19%), magnetic resonance imaging 103/148 (70%), Creatine kinase (CK) elevation at diagnosis 126/148 patients (85%). At last consultation (mean disease duration 5.0 ± 3.9 years), the mean physician’s global assessment of disease activity (PGA, NRS 0 – 10) was 1.6 ± SD 2.3, the mean manual muscle test (MMT, range 0 – 80, best 80) was 69.7 ± SD 19, the mean disease activity score (DAS, range 0 – 20, best 0) was 4.4 ± D 4.7, the mean CHAQ was 0.5 ± SD 0.8. MSA testing was performed on 88 patients (73% female); 42% tested positive; anti-NXP2 16%, anti-TIF1y 14%, anti-Mi2 6%, anti-Mi2 3%, anti-synthetase-antibodies 3%. The most common clinical feature was dysphagia in patients with anti-NXP2, calcinosis in patients with anti-TIF1y, lung involvement in patients with anti-synthetase antibodies, and pronounced muscle weakness in patients with anti-Mi2. Patients with anti-MDAS were characterized by frequent lung involvement, mucosal ulcers, fever and polycyclic arthritis of small joints. Muscle weakness tested by Childhood Myositis Assessment Score (CMAS) was significantly associated with an increased CK level. At last consultation, 32% and 14% received oral glucocorticoids (GC) < 0.2 mg/kg or ≥ 0.2 mg/kg body weight, respectively, 52% were treated with metnethotrexate (MTX) and 27% with intravenous immunoglobulins (last 12 months). PGA was ≤ 1 in 65% of patients at last consultation, 22% of those were off treatment.

**Conclusion:** Demographic and clinical parameters of patients with JDM in Germany are comparable to JDM-cohorts in other countries. MRI has gained diagnostic importance and is used more than twice as often as biopsy. MSA could be found in almost half of the patients. Clinical